Researchers at the University of California, San Diego School of Medicine say that losing the ability to make a particular kind of sugar molecule boosted disease protection in early hominids, and may have directed the evolutionary emergence of our ancestors, the genus Homo.

Researchers at the University of California, San Diego School of Medicine say that losing the ability to make a particular kind of sugar molecule boosted disease protection in early hominids, and may have directed the evolutionary emergence of our ancestors, the genus Homo . The findings, ...

(University of California - San Diego) Researchers at the University of California, San Diego School of Medicine say that losing the ability to make a particular kind of sugar molecule boosted disease protection in early hominids, and may have directed the evolutionary emergence of our ancestors, the genus Homo.

Blog posts in the Center for Global Development's "Rethinking U.S. Foreign Assistance Blog" and "ONE Blog" examine the outcome of the recent Millennium Challenge Corporation (MCC) board of directors meeting, highlighting changes to the selection criteria MCC uses to assess candidate countries' eligibility for funding.

Do more efficient and faster male birds win females over? New research from the United Kingdom suggests that the rock ptarmigan, the Arctic cousin of the grouse, does. University of Manchester researchers have found that male rock ptarmigans run up to 50% faster than females, making them significantly more efficient ...

Abbott (NYSE: ABT) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new Abbott Vysis ALK Break Apart FISH Probe test is ...

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc. Together, the partners have selected a drug candidate to advance into clinical development from the Epidermal Growth Factor Receptor ...

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, and the Cancer Immunotherapy Trials Network (CITN), a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center (COSC) headquartered at Fred Hutchinson Cancer Research ...

Drs. Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh presented a new non small cell lung cancer study at the 2011 Society of Surgical Oncology (SSO) conference in San Antonio, Texas. Dr. Landreneau is Director of the Lung Center at UPMC Shady Side Hospital as well as ...

Findings from two new studies presented today at the International Liver CongressTM confirm that there are options for clinicians to expand the pool of liver grafts for use in patients with liver disease.

When it comes to survival of the fittest, it's sometimes better to be an adaptable tortoise than a fitness-oriented hare, a Michigan State University evolutionary biologist says. In this week's Science magazine, Richard Lenski, MSU Hannah Distinguished Professor of Microbiology and Molecular Genetics, and colleagues show that more adaptable bacteria ...

In the next 20 years in large parts of China and India, there will be a 10% to 20% excess of young men because of sex selection and this imbalance will have societal repercussions, states an analysis in CMAJ (Canadian Medical Association Journal).